We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -1.89% | 2.60 | 2.50 | 2.70 | 2.65 | 2.60 | 2.65 | 387,964 | 08:02:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 10k | -2.04M | -0.0226 | -1.15 | 2.34M |
TIDMVAL
ValiRx PLC
20 June 2023
20 June 2023
ValiRx PLC ("ValiRx" or the "Company")
Virtual AGM Access
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces today an update regarding virtual access to the upcoming Annual General Meeting ("AGM").
In addition to welcoming shareholders to attend the AGM in-person at The Walbrook Building, 25 Walbrook, London, EC4N 8AF, a live webcast of the AGM presentation including Q&A will be made available. Commencing at 11:00am (UK time) on 28 June 2023, investors and analysts are invited to join via registration at https://brrmedia.news/VAL_AGM23 .
The recording of the webcast will also be available for playback from the Company's website, www.valirx.com, shortly after the event.
The Directors of the Company take responsibility for this announcement.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496 www.valirx.com Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com V Formation (Public Relations) +44 (0) 115 787 0206 www.vformation.biz Lucy Wharton - Senior PR Executive Sue Carr - Director lucy@vformation.biz sue@vformation.biz -------------------------- Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397 8900 Dale Bellis/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance) -------------------------- Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657 James Pope / Andy Thacker 0050 --------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAGPURWQUPWGMB
(END) Dow Jones Newswires
June 20, 2023 02:00 ET (06:00 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions